Advanced Masaoka-Koga stage as an independent predictor of thymoma recurrence after complete resection: myasthenia gravis was not an independent factor Authors: Jiwon Yang, Yeong-Bae Lee, Kun Woo Kim Published: 2025 ABSTRACT AbstractBackgroundAlthough myasthenia gravis (MG) commonly coexists with thymoma, its prognostic role in thymoma recurrence is controversial. Therefore, we aimed to identify clinical and pathological predictors of recurrence after thymectomy in a single-center cohort.MethodsWe retrospectively reviewed adult patients who underwent thymectomy for pathologically confirmed thymoma between January 2000 and December 2023 at a single tertiary center. Patients with at least 12 months of follow-up were included. Clinical, surgical, and pathological features were compared between patients with and without MG. Survival outcomes, including recurrence-free survival (RFS, R0 subgroup), progression-free survival (PFS, overall cohort), and overall survival (OS), were analyzed using Kaplan-Meier methods with log-rank tests. Independent predictors of recurrence were evaluated using Cox proportional hazards regression restricted to patients with R0 resection.ResultsPatients with MG were significantly younger and more likely to undergo transsternal extended thymectomy than those without MG. Although thymoma recurrence was more frequent in the MG group, MG status was not significantly associated with RFS or OS. Kaplan-Meier analysis showed that advanced-stage thymoma (stage III–IV) was associated with significantly shorter RFS, PFS, and OS compared with early-stage disease. In multivariate Cox regression restricted to R0 resections, advanced Masaoka stage remained an independent predictor of recurrence, while tumor size showed only a borderline association.ConclusionsAdvanced Masaoka stage is the strongest independent predictor of thymoma recurrence after complete resection. Tumor size demonstrated a borderline association, suggesting a potential contributory role that requires further validation. MG, although clinically important for peri- and post-operative management, was not independently associated with recurrence.Keywords: Thymoma, recurrence, Masaoka stage, tumor size, myasthenia gravis (MG) Highlight box Key findings • Advanced Masaoka-Koga stage independently predicts thymoma recurrence and overall survival (OS). • Myasthenia gravis (MG) was not independently associated with recurrence or OS in either total cohort or the R0-restricted subgroup; tumor size showed a borderline association with recurrence in the R0 subgroup but not with survival. What is known and what is new? • Thymoma often coexists with MG. Tumor stage, histology, completeness of resection, extent of thymectomy, and site of recurrence have been proposed as predictors of recurrence, while the prognostic value of MG has remained uncertain. • In a 23-year single-center surgical cohort, we separated outcomes into overall cohort (progression-free survival) and R0-only subgroup (recurrence-free survival) and conducted time-to-event analyses. Advanced Masaoka-Koga stage consistently predicted recurrence, MG was not independently associated with recurrence or OS, and tumor size showed an effect within the R0 subgroup. What is the implication, and what should change now? • Postoperative risk stratification and surveillance should prioritize tumor stage; follow-up intensity should be heightened in stage III–IV thymomas regardless of MG status. • MG remains clinically relevant for perioperative management, but it should not drive recurrence-risk counseling; the contributory role of tumor size in R0 patients warrants validation in larger cohorts. Introduction Thymoma is a typically slow-growing anterior mediastinal tumor that often remains clinically silent and is frequently identified incidentally during radiologic evaluations or in the context of neuromuscular symptoms attributable to myasthenia gravis (MG). The association between thymoma and MG is well-documented, with thymoma present in approximately 10–15% of patients with MG, and conversely, MG observed in 30–50% of patients diagnosed with thymoma (1,2). Despite this association, the impact of MG on the prognosis of thymoma—particularly regarding recurrence—remains controversial. Previous studies have proposed various predictors of thymoma recurrence, including World Health Organization (WHO) histologic subtype, Masaoka-Koga stage, completeness of resection, and tumor size (3). However, the prognostic value of MG status remains unclear, and its independent association with recurrence after surgery has yet to be established. In this retrospective cohort study, we aimed to evaluate clinicopathologic differences between thymoma patients with and without MG, and to identify factors independently associated with thymoma recurrence after surgical resection by comprehensively analyzing established prognostic variables, including MG status, tumor stage, tumor size, histologic type, and extent of resection. We present this article in accordance with the STROBE reporting checklist (available at https://gs.amegroups.com/article/view/10.21037/gs-2025-401/rc). Methods Subjects We retrospectively reviewed the clinical records of adult patients (age >19 years old) who underwent thymectomy between January 2000 and December 2023 at Gil Medical Center, Gachon University College of Medicine. We included only thymoma (thymic epithelial tumor) after excluding thymic carcinoma, thymic hyperplasia, thymic cyst, and other mediastinal mass (such as teratoma, neuroendocrine tumor, myxoma, etc.) by pathologic confirmation. Micronodular thymomas with lymphoid stroma (n=3) were excluded due to their distinct histologic behavior and lack of association with MG, making them unsuitable for comparative analysis (4). We classified patients into two groups: thymoma with MG and those without MG. Patients with MG were required to have typical clinical symptoms presenting fluctuating muscle weakness with fatigability and result of serum anti-AChR antibody by radioimmunoassay (considered positive when ≥0.5 nmol/L) with or without decremental response in Jolly test. Patients were classified into the MG group if they had a diagnosis of MG at any point during follow-up, regardless of the timing of onset relative to thymectomy. All patients should be followed at least 12 months. This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. The study was approved by the Ethics Committee of the Gil Medical Center (IRB No. GDIRB2024–154). Informed consent was waived in this retrospective study. Data collection Clinical data included age at MG symptom onset, age at thymectomy, sex, treatment, MG Foundation of America clinical classification (MGFA class) at initial visit, and MGFA postinterventional status at the latest visit. Surgical characteristics included surgical approach (transsternal vs. video-assisted thoracoscopy), type of resection [thymectomy (extended or total) vs. thymomectomy], completeness of tumor resection categorized as R0 (microscopically complete resection with negative margins), R1 (microscopic residual tumor), or R2 (macroscopic residual tumor) as determined by pathological assessment (5), tumor size, WHO classification of thymoma pathology (types A, AB, B1, B2, B3), and Masaoka-Koga stage (6). Additionally, information on MG perioperative management (e.g., steroid or immunosuppressive therapy, use of plasmapheresis or intravenous immunoglobulin), postoperative adjuvant radiotherapy or chemotherapy, thymoma recurrence, and mortality rate was collected. Radiotherapy was typically administered in patients with Masaoka-Koga stage II or higher, or based on the surgeon’s judgment. Statistical analysis Continuous variables were presented as mean ± standard deviation (SD) if normally distributed or as median with interquartile range (IQR) if non-normally distributed. Between-group comparisons were performed using the Mann-Whitney U test for continuous or ordinal variables and the Chi-squared test for categorical variables. Univariable logistic regression analysis was first performed to evaluate potential predictors of thymoma recurrence. Subsequently, multivariable logistic regression analysis was conducted using the enter method, including variables considered clinically relevant or previously reported as potential predictors (MG status, Masaoka-Koga stage, WHO classification, completeness of resection, surgical approach, adjuvant treatment, tumor size, age at onset, and sex). Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Adjuvant treatment was coded as a binary variable (administered vs. not administered) without distinguishing between radiotherapy, chemotherapy, or combined modalities. Completeness of resection was categorized as R0 versus R1–2 for statistical analyses. Complete case analysis was applied for missing data. Time-to-event outcomes were analyzed using Kaplan-Meier methods. Recurrence-free survival (RFS) was assessed in the R0 resection subgroup, while progression-free survival (PFS) and overall survival (OS) in the total cohort were also estimated. Survival curves were compared using the log-rank test, and the numbers of patients at risk were displayed below each curve. Independent predictors of recurrence were evaluated using Cox proportional hazards regression restricted to patients with R0 resection. Prespecified clinically relevant covariates included age, sex, MG status, tumor size, Masaoka-Koga stage, surgical approach, and adjuvant therapy. To avoid model overfitting given the limited number of events, covariates were restricted relative to the number of events, and proportional hazards assumptions were tested. All statistical analyses were performed using SPSS Statistics, version 21.0 (IBM Corp., Armonk, NY, USA). Results Among 213 patients with thymic mass, forty-five patients were in the thymoma with MG group and 168 patients were in those without MG group. Total 79 patients met all the inclusion criteria (Figure S1). Of the 79 patients, 32 were classified as having thymoma with MG, including 4 who developed MG after thymectomy. The remaining 47 patients had no clinical evidence of MG throughout the follow-up period. In the total cohort (n=79), the median age at thymectomy was 55 years (IQR, 47–62 years), and 44 patients (55.7%) were female. Histologically, B1–B3 thymomas accounted for 70.9% of cases. Advanced Masaoka-Koga stage (stage III–IV) was observed in 19 patients (24.1%). Complete resection (R0) was achieved in 64 patients (81.0%), while 8 (10.1%) and 7 (8.9%) underwent R1 and R2 resection, respectively. Among patients with advanced stage disease, R0 resection was achieved in 14 patients (73.7%), whereas 5 patients (26.3%) underwent R1/2 resection. Among the 64 patients who R0 resection, 12 (18.8%) developed recurrence during follow-up, of whom 11 had regional recurrence and 1 had distant recurrence. When comparing thymoma patients with or without MG (Table 1), patients with thymoma with MG showed younger age at onset (median: 50 years), longer follow-up duration, and higher rate of transsternal extended thymectomy (96.9%), advance Masaoka-Koga stage (37.5%), thymoma recurrence (37.5%) and death (25.0%). Type B histology was more frequent in patients with thymoma with MG (81.2%) compared to those without MG (63.8%), with a trend toward statistical significance (P=0.07). The pattern of thymoma recurrence did not differ significantly between thymoma patients with and without MG. Table 1Comparison between thymoma with and without MGVariableThymoma with MG (n=32)Thymoma without MG (n=47)P valueSex (female, %)16 (50.0)28 (59.6)0.27Thymectomy age, years50 [41–55]59 [50–66]0.001WHO classificationA/AB/B1: 15 (46.9)A/AB/B1: 32 (68.1)0.07B2/B3: 17 (53.1)B2/B3: 15 (31.9)B histology: 26 (81.2)B histology: 30 (63.8)Masaoka-Koga stageStage I, II: 20 (62.5)Stage I, II: 40 (85.1)0.02Stage III, IV: 12 (37.5)Stage III, IV: 7 (14.9)Tumor size, cm5.9 (4.18–7.0)6.4 (4.6–8.0)0.34Surgical approachTranssternal: 30 (93.8)Transsternal: 26 (55.3)<0.001Video-assisted transthoracic: 2 (6.3)Video-assisted transthoracic: 21 (44.7)Surgical extentExtended thymectomy: 31 (96.9)Extended thymectomy: 28 (59.6)0.001Total thymectomy: 0Total thymectomy: 14 (29.8)Thymomectomy†: 1 (3.1)Thymomectomy†: 5 (10.6)Completeness of resection‡R0: 26 (81.3)R0: 38 (80.9)0.44R1: 2 (6.3)R1: 6 (12.8)R2: 4 (12.5)R2: 3 (6.4)Adjuvant treatmentRT: 15 (46.9)RT: 27 (57.4)0.78CT: 1 (3.1)CT: 2 (4.3)Both: 2 (6.3)Both: 2 (4.3)Thymoma recurrence12 (37.5)6 (12.8)0.01Type of recurrenceLocal: 0Local: 10.57Regional: 11Regional: 5Distant: 1Distant: 0Time to recurrence, month75.5 [25.0–132.0]28.0 [9.0–70.7]0.14Death during follow-up8 (25.0)3 (6.4)0.02Follow-up duration, months107.0 [46.5–184.7]47 [30–84]0.001Variables are presented as median [interquartile range] or frequency (percent) according to variable type. †, tumor-only resection with partial preservation of thymic tissue; ‡, R0 indicates complete resection with negative margins; R1 indicates microscopic residual disease; R2 indicates macroscopic residual tumor. CT, chemotherapy; MG, myasthenia gravis; RT, radiotherapy; WHO, World Health Organization. Comparison between thymoma with and without MG Variables are presented as median [interquartile range] or frequency (percent) according to variable type. †, tumor-only resection with partial preservation of thymic tissue; ‡, R0 indicates complete resection with negative margins; R1 indicates microscopic residual disease; R2 indicates macroscopic residual tumor. CT, chemotherapy; MG, myasthenia gravis; RT, radiotherapy; WHO, World Health Organization. Among patients with thymoma with MG, the majority presented with ocular symptoms (MGFA class I, 67.9%), while 32.1% had generalized symptoms (class II–III) before thymectomy. At the last follow-up, 65.6% remained in class I and 90.6% showed improved or stable status, although 28.1% experienced MG crisis requiring intubation after thymectomy during follow-up. Preoperative immunosuppressive treatment was rarely administered (3.1%), whereas 90.3% received postoperative steroid or immunosuppressive therapy. Anti-AChR antibody titers remained detectable during follow-up (median 7.06 nmol/L) (Table S1). Univariate logistic regression analysis identified several factors associated with thymoma recurrence (Table 2). The presence of MG was significantly associated with recurrence (OR =4.1, 95% CI: 1.34–12.52, P=0.01), as were longer follow-up duration (OR =1.01, 95% CI: 1.00–1.01, P=0.007), transsternal surgical approach (OR =9.59, 95% CI: 1.19–77.02, P=0.03), adjuvant treatment (OR =3.97, 95% CI: 1.04–15.14, P=0.04), tumor size (OR = 1.22, 95% CI: 1.01–1.47, P=0.04), B2/B3 histology (OR =2.99, 95% CI: 1.01–8.86, P=0.048), and advanced Masaoka-Koga stage (OR =10.41, 95% CI: 3.12–34.72, P<0.001). Gender, age at thymoma operation, and extent of thymectomy were not significantly associated with recurrence, while incomplete resection showed borderline association. Table 2Univariate and multivariate logistic regression analysis for thymoma recurrenceVariableUnivariateMultivariateOR95% CIP valueOR95% CIPvalueGender1.350.47, 3.860.580.460.10, 2.280.34Presence of MG4.11.34, 12.520.012.310.32, 16.950.41Age at thymectomy0.970.93, 1.010.161.020.94, 1.110.59Total follow-up duration1.011.00, 1.020.0071.010.99, 1.020.16Surgical approach (transsternal vs. VATS)9.591.19, 77.020.0310.460.29, 382.140.20Surgical extent (extended thymectomy vs. non-extended)3.350.69, 16.090.131.420.19, 10.380.73Completeness of resection (R1/2 vs. R0)2.890.86, 9.680.0913.60.19, 9.330.76Tumor size1.221.01, 1.470.041.290.97, 1.740.08WHO classification (B2/3 vs. A/AB/B1)2.991.01, 8.860.0481.100.24, 5.030.90Masaoka-Koga stage (III–IV vs. I–II)10.413.12, 34.72<0.0016.291.16, 34.290.03Adjuvant treatment (yes vs. no)3.971.04, 15.140.044.080.74, 22.600.11R0, complete resection; R1, microscopic residual tumor; R2, macroscopic residual tumor. CI, confidence interval; MG, myasthenia gravis; OR, odds ratio; VATS, video-assisted thoracoscopic surgery; WHO, World Health Organization. Univariate and multivariate logistic regression analysis for thymoma recurrence R0, complete resection; R1, microscopic residual tumor; R2, macroscopic residual tumor. CI, confidence interval; MG, myasthenia gravis; OR, odds ratio; VATS, video-assisted thoracoscopic surgery; WHO, World Health Organization. In the multivariable logistic regression analysis, advanced Masaoka stage (stage III–IV) was identified as an independent predictor of thymoma recurrence, with an OR of 6.55 (95% CI: 1.12–38.20, P=0.04). Other variables, including MG status, completeness of resection, surgical approach, extent of thymectomy, tumor size, age, sex, and WHO classification, were not significantly associated with recurrence. Consistently, Kaplan-Meier survival analysis demonstrated that patients with advanced Masaoka-Koga stage had significantly shorter PFS compared with those with early stage disease in the total cohort including R0 and R1/2 resections (log-rank P=0.001; Figure 1A), as well as shorter RFS in the R0 resection subgroup (log-rank P<0.001; Figure 1B). In the Cox proportional hazards model restricted to patients with R0 resection, in order to minimize the potential confounding effect of incomplete resection, both advanced stage disease (HR 4.57, 95% CI: 1.05–19.80, P=0.04) while larger tumor size showed only a borderline association (per 1-cm increase: HR 1.37, 95% CI: 0.99–1.91, P=0.06) (Table 3). Kaplan-Meier survival curves according to Masaoka-Koga stage. (A) Progression-free survival in the total cohort (log-rank P=0.001). (B) Recurrence-free survival in patients who underwent complete (R0) resection (log-rank P<0.001). (C) Overall survival in the total cohort (log-rank P=0.047). Patients with advanced stage (III/IV) showed significantly worse outcomes compared with those with early stage (I/II). Numbers below the x-axis indicate the number of patients at risk at each time point. Statistical significance was assessed using the log-rank test. Table 3Multivariable Cox proportional hazards analysis for recurrence-free survivalVariableHR95% CIP valueMasaoka stage (III–IV vs. I–II)4.6981.122–19.6630.03MG status (MG vs. non-MG)0.6970.150–3.2450.65Tumor size (per 1 cm)1.3230.990–1.7670.06Age at onset (per year)1.0090.150–1.0870.82Sex (male vs. female)0.5680.144–2.2430.42WHO classification (B2/3 vs. A/AB/B1)1.7390.416–7.2660.45Surgical extent (extended vs. non)NE––Adjuvant therapy (yes vs. no)2.2160.503–9.7530.29The HR for surgical approach was not estimable due to sparse events in the VATS group. Results are derived from Cox proportional hazards regression in the R0 resection subgroup. CI, confidence interval; HR, hazard ratio; MG, myasthenia gravis; NE, not estimable; VATS, video-assisted thoracoscopic surgery; WHO, World Health Organization. Multivariable Cox proportional hazards analysis for recurrence-free survival The HR for surgical approach was not estimable due to sparse events in the VATS group. Results are derived from Cox proportional hazards regression in the R0 resection subgroup. CI, confidence interval; HR, hazard ratio; MG, myasthenia gravis; NE, not estimable; VATS, video-assisted thoracoscopic surgery; WHO, World Health Organization. Apart from advanced Masaoka-Koga stage (log-rank P=0.047; Figure 1C), no other variable, including tumor size, was a significant predictor of OS. Discussion In our single-center experience, the age at thymectomy had a median of 55 years. Younger age at the thymectomy in the thymoma with MG group may be attributed to the fact that thymomas are frequently asymptomatic and are more likely to be detected earlier when accompanied by MG-related symptoms. In contrast, a higher proportion of advanced Masaoka-Koga stage (III–IV) was observed in MG-associated thymoma in our study, which seems contrary to the aforementioned explanation. This paradox likely reflects a referral bias inherent to a tertiary neurology-thoracic surgery center, where patients with more complex or invasive disease are preferentially referred for combined management. Accordingly, our MG cohort may represent a more advanced subset of thymoma cases rather than the full clinical spectrum typically seen in population-based studies. Type B thymoma was the most frequently observed histological subtype in both groups. Tumor size and sex distribution were comparable between the groups, consistent with previous studies (2,7,8). Type B thymomas, particularly subtypes B1 and B2, are characterized by an abundance of lymphocytes and a prominent immunological milieu, as defined by their histopathological morphology, and are highly associated with MG (7-9). The predominance of transsternal extended thymectomy in thymoma with MG group may reflect the surgical preference for more aggressive resection in patients with MG to remove completely ectopic thymic tissue in addition to the tumor itself and to optimize neurological outcomes. Thymoma has malignant potential, with the ability to invade adjacent great vessels, lymphatics, and cardiopulmonary structures. Accordingly, there remains a possibility of recurrence even after complete resection, although such cases are rare (10). The average relapse-free interval for thymoma has been reported to be approximately five years, with an overall recurrence rate of 7–8%. Although complete resection of thymoma is achieved, local recurrence may still occur long after a prolonged disease-free interval, with cases reported even 30 years postoperatively (10-12). A study from another Korean medical center reported an overall recurrence rate of 13.4% and a median disease-free interval of 52 months (13). In our cohort, the median time to recurrence was 55.5 months. The recurrence rate was 37.5% in patients with thymoma with MG, compared to 14.9% in those without MG. These findings are generally consistent with previous studies. Several factors have been widely accepted as potential predictors of thymoma recurrence, including WHO histological subtype, advanced Masaoka stage, incomplete initial resection, extent of thymectomy, postoperative adjuvant therapy, site of recurrence, and larger tumor size and some of which may be interrelated (10,13-16). However, the prognostic significance of MG coexistence in thymoma, including its association with recurrence, remains controversial. In the past, it was considered that unfavorable effect on postoperative outcomes might be raised from perioperative myasthenia crisis and increased perioperative morbidity. Independent of perioperative myasthenic crisis, some studies have suggested that the presence of MG may be a negative prognostic factor for long-term outcomes (17-19). In contrast, other studies have indicated that MG may not adversely affect prognosis and might even be associated with improved outcomes (20-22). In the present study, advanced Masaoka-Koga stage emerged as the key independent predictor of thymoma recurrence in the final multivariate model, underscoring the central role of tumor invasiveness in recurrence risk. Although MG showed an association with recurrence in univariate analysis, this relationship did not remain significant in multivariate logistic regression or Kaplan-Meier analyses after adjustment for stage and other clinical variables. In our study, recurrence analyses were performed separately for the overall cohort and the R0 resection subgroup to minimize confounding by incomplete resections. Because recurrence after R1/R2 resection often reflects residual disease rather than new tumor biology, restricting Cox regression and Kaplan–Meier analyses to R0 cases enabled more precise assessment of true prognostic factors. While previous large-scale series have consistently identified Masaoka-Koga stage as a major determinant of recurrence, the prognostic significance of MG has remained uncertain. Our findings refine this understanding by demonstrating that, even within a smaller but clinically well-characterized single-center cohort, MG status does not independently influence recurrence once tumor invasiveness is accounted for. This clarification offers clinical value by reinforcing the dominance of tumor stage over MG in postoperative risk stratification. Tumor size also appeared to affect recurrence risk. Larger tumors were significantly associated with recurrence in univariate logistic regression and Kaplan-Meier analyses, whereas the association was borderline in multivariate logistic regression (P=0.08) and Cox regression (P=0.06). These findings suggest that tumor size may contribute to recurrence risk, although its independent effect was attenuated after adjustment for stage and other covariates. Given the limited number of events, tumor size should be regarded as a potential prognostic factor requiring validation in larger cohorts. The median time to recurrence was numerically longer in the MG group than in the non-MG group (72.5 vs. 28.0 months; P=0.14), and overall mortality was also higher in the MG group. However, these findings are unlikely to reflect a direct effect of MG. Rather, they are better explained by confounding factors, particularly the higher frequency of extended thymectomy among MG patients, which may delay early recurrence, and the greater need for long-term immunosuppressive or symptomatic management, which naturally prolongs surveillance. Taken together, these results suggest that the observed differences are largely attributable to tumor stage, surgical extent, and treatment-related factors, rather than to MG itself. Although the sample size is limited, this single-center cohort offers several advantages that complement findings from large multicenter registries. The homogeneity of surgical approach, pathological evaluation, and follow-up protocols minimizes inter-institutional variability, allowing more consistent assessment of clinicopathologic correlations. In addition, the integration of detailed neurological data—such as MG severity, antibody titers, and postoperative immunosuppressive management—is rarely available in multicenter surgical databases. Collectively, this study provides clinically detailed evidence supporting the dominant role of tumor invasiveness rather than MG status in predicting recurrence after complete resection. Nevertheless, several limitations should be acknowledged. First, the retrospective, single-center design and relatively small sample size may limit the generalizability of our findings. Despite the long observational period, selection and information biases inherent to retrospective data collection could not be entirely excluded. Second, the follow-up duration and mortality differed between the MG and non-MG groups, potentially influencing recurrence estimates through underdetection of late recurrences in the non-MG group and informative censoring in the MG group. Postoperative immunosuppressive therapy was administered to almost all MG patients but not to any non-MG patients, precluding its inclusion as a covariate in multivariable analyses and leaving the possibility of residual confounding. Moreover, as most patients were treated before the introduction of recent molecular-targeted therapies for MG, the immunosuppressive regimens largely reflected conventional corticosteroid, azathioprine, or calcineurin inhibitor-based therapy, which may not fully represent current practice. Third, the proportion of incomplete resections (R1/R2) in our cohort was relatively high compared to typical rates reported in thymoma surgery, reflecting the complexity of cases referred to a tertiary center. Finally, due to the limited number of recurrence and death events—particularly in subgroup analysis—certain associations may be underpowered or unstable. Larger prospective studies are warranted to confirm the recurrence predictors identified in this study. Conclusions In conclusion, this observational study indicates that MG itself is not directly associated with thymoma recurrence or mortality. Advanced Masaoka–Koga stage consistently emerged as the strongest predictor, while tumor size showed only a borderline association. These findings highlight tumor invasiveness, rather than MG, as the key determinants of outcome underscoring the need for intensive surveillance in patients with advanced disease. Supplementary The article’s supplementary files as Acknowledgments The authors thank Dr. Dong-Hyun Lee for his help with English editing and statistical advice. This contributor had no involvement in the study design or data interpretation. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. The study was approved by the Ethics Committee of the Gil Medical Center (IRB No. GDIRB2024–154). Informed consent was waived in this retrospective study. Footnotes Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://gs.amegroups.com/article/view/10.21037/gs-2025-401/rc Funding: This work was supported by the Gachon University research fund of 2023 (GCU-202309260001) and the research fund of 2024 (GCU-202410410001). Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://gs.amegroups.com/article/view/10.21037/gs-2025-401/coif). The authors have no conflicts of interest to declare. Data Sharing Statement Available at https://gs.amegroups.com/article/view/10.21037/gs-2025-401/dss References Available at https://gs.amegroups.com/article/view/10.21037/gs-2025-401/prf Supplementary Materials The article’s supplementary files as Data Availability Statement Available at https://gs.amegroups.com/article/view/10.21037/gs-2025-401/dss